Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling
The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Abstract
Angiogenesis is a complex biological process involving the coordinated modulation of many genes. Histone deacetylases (HDAC) are a growing family of enzymes that mediate the availability of chromatin to the transcriptional machinery. Trichostatin-A (TSA) and suberoylanilide hydroxamic acid (SAHA), two HDAC inhibitors known to relieve gene silencing, were evaluated as potential antiangiogenic agents. TSA and SAHA were shown to prevent vascular endothelial growth factor (VEGF)-stimulated human umbilical cord endothelial cells (HUVEC) from invading a type I collagen gel and forming capillary-like structures. SAHA and TSA inhibited the VEGF-induced formation of a CD31-positive capillary-like network in embryoid bodies and inhibited the VEGF-induced angiogenesis in the CAM assay. TSA also prevented, in a dose-response relationship, the sprouting of capillaries from rat aortic rings. TSA inhibited in a dose-dependent and reversible fashion the VEGF-induced expression of VEGF receptors, VEGFR1, VEGFR2, and neuropilin-1. TSA and SAHA upregulated the expression by HUVEC of semaphorin III, a recently described VEGF competitor, at both mRNA and protein levels. This effect was specific to endothelial cells and was not observed in human fibroblasts neither in vascular smooth muscle cells. These observations provide a conspicuous demonstration that HDAC inhibitors are potent anti-angiogenic factors altering VEGF signaling.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“inhibition of HDAC attenuates VEGF signalling, which is important for vascular morphogenesis and endothelial differentiation [195].”
From Transition from inflammation to proliferation: a critical step during wound healing (2016) · cites this paper as [195]
Citations
Cites
Vascular endothelial growth factor (VEGF) and its receptors
NEUFELD, G., COHEN, T., GENGRINOVITCH, S., & POLTORAK, Z. (1999) · The FASEB Journal · doi:10.1096/fasebj.13.1.9 · Cited by 3,483 · cited 7×
“…e ect of TSA on the phenotype of HUVEC was further evaluated by measuring the steady-state level of the mRNAs coding for the VEGF receptors, VEGFR1, its soluble form sVEGFR1, VEGFR2 (Neufeld et al., 1999), and the recently identi®ed co-receptor for VEGF165, neuropilin-1 (Miao et al., 1999).”
BackgroundInfluentialYoshida, M., Kijima, M., Akita, M., & Beppu, T. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)44885-x · Cited by 1,854
Histone acetylation and transcriptional regulatory mechanisms
Struhl, K. (1998) · Genes & Development · doi:10.1101/gad.12.5.599 · Cited by 1,815 · cited 4×
“HDAC have been associated with a repression of transcription (Struhl, 1998) and their inhibition should relieve gene silencing.”
BackgroundInfluentialAntiangiogenic therapy of experimental cancer does not induce acquired drug resistance
Boehm, T., Folkman, J., Browder, T., & O'Reilly, M. S. (1997) · Nature · doi:10.1038/37126 · Cited by 1,683 · cited 1×
“Antiangiogenic therapy of cancers o ers the possibility of a low toxicity treatment without acquisition of drug resistance due to the genetic stability, homogeneity and low mutational rate of endothelial cells (Boehm et al., 1997).”
BackgroundA class of hybrid polar inducers of transformed cell differentiation inhibits histone deacetylases
Richon, V. M., Emiliani, S., Verdin, E., Webb, Y., Breslow, R., Rifkind, R. A., & Marks, P. A. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.6.3003 · Cited by 914 · cited 2×
“By using speci®c inhibitors, mainly TSA and SAHA (Yoshida et al., 1990; Richon et al., 1998) in di erent models based on in vitro, ex vivo and in vivo assays, we demonstrated that HDAC inhibition suppresses the spontaneous or VEGFinduced angiogenesis.”
BackgroundMethodSelf-citationHistone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes
Kim, M. S., Kwon, H. J., Lee, Y. M., Baek, J. H., Jang, J.-E., Lee, S.-W., Moon, E.-J., Kim, H.-S., Lee, S.-K., Chung, H. Y., et al. (2001) · Nature Medicine · doi:10.1038/86507 · Cited by 731 · cited 7×
“At the time that we were preparing this manuscript, a study reporting the involvement of histone deacetylases in angiogenesis was published by Kim et al. (2001).”
BackgroundMethodInfluentialKijima, M., Yoshida, M., Sugita, K., Horinouchi, S., & Beppu, T. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)41547-5 · Cited by 514
Embryonic stem cells differentiate in vitro to endothelial cells through successive maturation steps
Vittet, D., Prandini, M., Berthier, R., Schweitzer, A., Martin-Sisteron, H., Uzan, G., & Dejana, E. (1996) · Blood · doi:10.1182/blood.v88.9.3424.bloodjournal8893424 · Cited by 472 · cited 1×
“Capillary-like structures formation was analysed by the expression of CD31 in whole mount immuno¯uorescence as reported by Vittet et al. (1996).”
MethodNeuropilin-1 Mediates Collapsin-1/Semaphorin III Inhibition of Endothelial Cell Motility
Miao, H.-Q., Soker, S., Feiner, L., Alonso, J. L., Raper, J. A., & Klagsbrun, M. (1999) · The Journal of Cell Biology · doi:10.1083/jcb.146.1.233 · Cited by 458 · cited 5×
“…e ect of TSA on the phenotype of HUVEC was further evaluated by measuring the steady-state level of the mRNAs coding for the VEGF receptors, VEGFR1, its soluble form sVEGFR1, VEGFR2 (Neufeld et al., 1999), and the recently identi®ed co-receptor for VEGF165, neuropilin-1 (Miao et al., 1999).”
BackgroundInfluentialDeroanne, C. (2001) · Cardiovascular Research · doi:10.1016/s0008-6363(00)00233-9 · Cited by 256 · cited 1×
“Culture medium, Oncogene HUVEC were induced to organize into a network of tube-like structures as described (Deroanne et al., 1996, 2001).”
MethodSelf-citation
Cited by
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Transition from inflammation to proliferation: a critical step during wound healing
Landén, N. X., Li, D., & Ståhle, M. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2268-0 · Cited by 1,980
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Histone deacetylase inhibitors: molecular mechanisms of action
Xu, W. S., Parmigiani, R. B., & Marks, P. A. (2007) · Oncogene · doi:10.1038/sj.onc.1210620 · Cited by 1,542
“TSA, vorinostat, FK228, butyrate and LAQ824 were found to repress angiogenesis in vitro and in vivo, and reduce expression of pro-angiogenesis factors, including HIF-1a and VEGF (Deroanne et al., 2002; Bolden et al., 2006; Liang et al., 2006).”
BackgroundInfluentialHistone Deacetylase Inhibitors as Anticancer Drugs
Eckschlager, T., Plch, J., Stiborova, M., & Hrabeta, J. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18071414 · Cited by 1,206
“In addition, HDAC inhibitors decrease the levels of the VEGF receptors in neuroblastoma cells [113].”
BackgroundHistone deacetylases and cancer
Glozak, M. A., & Seto, E. (2007) · Oncogene · doi:10.1038/sj.onc.1210610 · Cited by 1,031
Histone Deacetylase Inhibitors in Cancer Therapy
Lane, A. A., & Chabner, B. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1291 · Cited by 874
“In addition, HDAC inhibitors decrease expression of the vascular endothelial growth factor receptor.(44) HDAC inhibition also increases generation of intracellular reactive oxygen species, and impairs handling of misfolded proteins by influencing endoplasmic reticulum stress responses.”
BackgroundHistone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code
THIAGALINGAM, S., CHENG, K., LEE, H. J., MINEVA, N., THIAGALINGAM, A., & PONTE, J. F. (2003) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2003.tb05964.x · Cited by 700
SIRT1 Controls Endothelial Angiogenic Functions During Vascular Growth
Potente, M., Ghaeni, L., Baldessari, D., Mostoslavsky, R., Rossig, L., Dequiedt, F., Haendeler, J., Mione, M., Dejana, E., Alt, F. W., et al. (2007) · Genes & Development · doi:10.1101/gad.435107 · Cited by 608
“Class I and II HDACs play important roles in the transcriptional control of endothelial gene expression and vascular development (Kim et al. 2001; Deroanne et al. 2002; Rossig et al. 2002, 2005; Illi et al. 2003, 2005; Chang et al. 2006).”
Background(2011) · PubMed Central · Cited by 560
The Pathogenesis of Endometriosis: Molecular and Cell Biology Insights
Laganà, A. S., Garzon, S., Götte, M., Viganò, P., Franchi, M., Ghezzi, F., & Martin, D. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20225615 · Cited by 479
HDAC and HDAC Inhibitor: From Cancer to Cardiovascular Diseases
Yoon, S., & Eom, G. H. (2016) · Chonnam Medical Journal · doi:10.4068/cmj.2016.52.1.1 · Cited by 464
The epigenetic effects of butyrate: potential therapeutic implications for clinical practice
Berni Canani, R., Di Costanzo, M., & Leone, L. (2012) · Clinical Epigenetics · doi:10.1186/1868-7083-4-4 · Cited by 431
“Butyrate was found to repress angiogenesis in vitro and in vivo, and reduce expression of proangiogenesis factors, including hypoxia inducible factors (HIF-1a) and vascular endothelial growth factor (VEGF) [12-14].”
Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy
Carew, J. S., Giles, F. J., & Nawrocki, S. T. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.037 · Cited by 421
“shown to decrease the expression of several proangiogenic factors, including vascular endothelial growth factor (VEGF) and hypoxia-inducible factor-1a (HIF1a) [33,34].”
BackgroundHistone Deacetylase Inhibitors
(2004) · Advances in Cancer Research · doi:10.1016/s0065-230x(04)91004-4 · Cited by 415
Regulation of Angiogenesis by Oxygen and Metabolism
Fraisl, P., Mazzone, M., Schmidt, T., & Carmeliet, P. (2009) · Developmental Cell · doi:10.1016/j.devcel.2009.01.003 · Cited by 413
“Their inhibitory capacity relies on silencing angiogenic factors (VEGF, eNOS) and upregulating angiogenic inhibitors (Deroanne et al., 2002; Michaelis et al., 2004).”
BackgroundHe, L., Jhong, J.-H., Chen, Q., Huang, K.-Y., Strittmatter, K., Kreuzer, J., DeRan, M., Wu, X., Lee, T.-Y., Slavov, N., et al. (2021) · Cell Reports · doi:10.1016/j.celrep.2021.109955 · Cited by 354
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Wagner, J. M., Hackanson, B., Lübbert, M., & Jung, M. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0012-4 · Cited by 338
Histone deacetylation in epigenetics: An attractive target for anticancer therapy
Mai, A., Massa, S., Rotili, D., Cerbara, I., Valente, S., Pezzi, R., Simeoni, S., & Ragno, R. (2005) · Medicinal Research Reviews · doi:10.1002/med.20024 · Cited by 319
Hull, E. E., Montgomery, M. R., & Leyva, K. J. (2016) · BioMed Research International · doi:10.1155/2016/8797206 · Cited by 313
Epigenetic and Chromatin Modifiers As Targeted Therapy of Hematologic Malignancies
Bhalla, K. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.16.600 · Cited by 308
Nonhistone protein acetylation as cancer therapy targets
Singh, B. N., Zhang, G., Hwa, Y. L., Li, J., Dowdy, S. C., & Jiang, S.-W. (2010) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.62 · Cited by 300
Histone deacetylase inhibitor (HDACI) mechanisms of action: Emerging insights
Bose, P., Dai, Y., & Grant, S. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.04.004 · Cited by 280
“…et al., 2010), vi. interference with proteasome function (Fotheringham et al., 2009; C. S. Mitsiades et al., 2004), vii. anti-angiogenic effects (Deroanne et al., 2002; Qian et al., 2004), viii. generation of the pro-apoptotic lipid second messenger ceramide (Maggio et al., 2004) and ix.…”
BackgroundHistone deacetylase inhibition reduces myocardial ischemia‐reperfusion injury in mice
Granger, A., Abdullah, I., Huebner, F., Stout, A., Wang, T., Huebner, T., Epstein, J. A., & Gruber, P. J. (2008) · The FASEB Journal · doi:10.1096/fj.08-108548 · Cited by 273
“Interestingly, pretreatment of hypoxic myocytes with the HDACI Scriptaid repressed this induction to baseline levels with no significant change at the mRNA levels (data not shown), extending observations in other cell types (28, 29).”
BackgroundRamalingam, S. S., Maitland, M. L., Frankel, P., Argiris, A. E., Koczywas, M., Gitlitz, B., Thomas, S., Espinoza-Delgado, I., Vokes, E. E., Gandara, D. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9094 · Cited by 273
“factor , and tubulin, also may contribute to the anticancer effects of HDAC inhibitors.(7-10) These”
BackgroundLin, H., Hu, C., Chan, H., Liew, Y., Huang, H., Lepescheux, L., Bastianelli, E., Baron, R., Rawadi, G., & Clément‐Lacroix, P. (2007) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0707165 · Cited by 272
“…the upregulation of the cell-cycle inhibitor p21 (Waf/Cip1) (Chung et al., 2003; Nishida et al., 2004; Jungel et al., 2006); inhibit angiogenesis (Deroanne et al., 2002; Mie Lee et al., 2003; Kim et al., 2004; Michaelis et al., 2004; Qian et al., 2004); and decrease the expression of…”
BackgroundLysine acetyltransferases and lysine deacetylases as targets for cardiovascular disease
Li, P., Ge, J., & Li, H. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-019-0235-9 · Cited by 269
The role of neuropilins in cancer
Ellis, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0538 · Cited by 263
Histone deacetylase inhibitors: from target to clinical trials
Kelly, W. K., O’Connor, O. A., & Marks, P. A. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.12.1695 · Cited by 253
Taxonomy, Fermentation, Isolation and Biological Activities.
MORI, H., URANO, Y., ABE, F., FURUKAWA, S., FURUKAWA, S., TSURUMI, Y., SAKAMOTO, K., HASHIMOTO, M., TAKASE, S., HINO, M., et al. (2003) · The Journal of Antibiotics · doi:10.7164/antibiotics.56.72 · Cited by 236
Targeting tumor angiogenesis with histone deacetylase inhibitors
Ellis, L., Hammers, H., & Pili, R. (2009) · Cancer Letters · doi:10.1016/j.canlet.2008.11.012 · Cited by 232
“Previous studies conducted by Deroanne et al also showed that TSA and vorinostat inhibit VEGF and VEGF receptors VEGFR1 and VEGFR2, as well as up-regulate the VEGF competitor protein, semaphorin II [58].”
ResultHistone deacetylase inhibitors: Multifunctional anticancer agents
Liu, T., Kuljaca, S., Tee, A., & Marshall, G. M. (2006) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2005.12.006 · Cited by 230
Qian, D. Z., Wang, X., Kachhap, S. K., Kato, Y., Wei, Y., Zhang, L., Atadja, P., & Pili, R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0540 · Cited by 229
Histone Deacetylase Inhibitors: Current Status and Overview of Recent Clinical Trials
Ma, X., Ezzeldin, H. H., & Diasio, R. B. (2009) · Drugs · doi:10.2165/11315680-000000000-00000 · Cited by 227
“The VEGF-induced transcription of VEGFR1 and VEGFR2 in endothelial cells could be inhibited by trichostatin A; VEGF-induced angiogenesis was also inhibited by trichostatin A and vorinostat.([81]) Another protein required in angiogenesis, the endothelial chemokine receptor CXCR4, was repressed by panobinostat at mRNA a…”
Epigenetic Regulation of Vascular Endothelial Gene Expression
Matouk, C. C., & Marsden, P. A. (2008) · Circulation Research · doi:10.1161/circresaha.107.171025 · Cited by 227
Valproic Acid Inhibits Angiogenesis in Vitro and in Vivo
Michaelis, M., Michaelis, U. R., Fleming, I., Suhan, T., Cinatl, J., Blaheta, R. A., Hoffmann, K., Kotchetkov, R., Busse, R., Nau, H., et al. (2004) · Molecular Pharmacology · doi:10.1124/mol.65.3.520 · Cited by 227
“…to direct effects that result in the destruction of tumor cells or induction of differentiation (for review, see Marks et al., 2001), HDAC inhibitors are reported to inhibit hypoxia- and vascular endothelial growth factor (VEGF)induced angiogenesis (Kim et al., 2001; Deroanne et al., 2002).”
BackgroundJaboin, J. J., Wild, J., Hamidi, H., Khanna, C., Kim, C. J., Robey, R. W., Bates, S. E., & Thiele, C. J. (2002) · PubMed · Cited by 247
Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy
Singh, A. K., Bishayee, A., & Pandey, A. K. (2018) · Nutrients · doi:10.3390/nu10060731 · Cited by 221
“HDAC 10 KD causes reduced vascular endothelial growth factor of receptor 1 and 2 (VEGF 1 and 2) and increased sensitivity towards DNA damage in cancer cells [67].”
BackgroundEpigenetic therapy of cancer with histone deacetylase inhibitors
Aparna, S., Lakshmaiah, K., Jacob, L., Lokanatha, D., & Saldanha, S. (2014) · Journal of Cancer Research and Therapeutics · doi:10.4103/0973-1482.137937 · Cited by 217
Inhibitors of histone deacetylase as antitumor agents: A critical review
Manal, M., Chandrasekar, M. J. N., Gomathi Priya, J., & Nanjan, M. J. (2016) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2016.05.005 · Cited by 216
Role of nitric oxide in placental vascular development and function
Krause, B. J., Hanson, M. A., & Casanello, P. (2011) · Placenta · doi:10.1016/j.placenta.2011.06.025 · Cited by 216
“HDACinhibition reduces the VEGF-induced angiogenesis through down-regulation of VEGFR-1 and -2 expression [135], whilst histone methyl transferase activity is required for migration and vessel sprouting [136].”
BackgroundTranscriptional and posttranscriptional regulation of endothelial nitric oxide synthase expression
Searles, C. D. (2006) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00457.2005 · Cited by 210
“NO is known to be a mediator of angiogenesis (96), and trichostatin A (TSA), an inhibitor of histone deacetylase (HDAC) activity, is able to prevent VEGF- or hypoxia-induced angiogenesis (25, 59).”
BackgroundTrends and Challenges in Tumor Anti-Angiogenic Therapies
Jászai, J., & Schmidt, M. (2019) · Cells · doi:10.3390/cells8091102 · Cited by 208
“HDACs are considered as potential anticancer drugs with multimodal properties [276] including potent angiogenesis inhibitor activity which alters VEGF signaling [277].”
BackgroundLiu, L., Chang, H., Chiang, L., & Hung, W. (2003) · PubMed · Cited by 227
Fouladi, M., Park, J. R., Stewart, C. F., Gilbertson, R. J., Schaiquevich, P., Sun, J., Reid, J. M., Ames, M. M., Speights, R., Ingle, A. M., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.25.9119 · Cited by 199
Rössig, L., Li, H., Fisslthaler, B., Urbich, C., Fleming, I., Förstermann, U., Zeiher, A. M., & Dimmeler, S. (2002) · Circulation Research · doi:10.1161/01.res.0000037983.07158.b1 · Cited by 198
Waltregny, D., Glénisson, W., Tran, S. L., North, B. J., Verdin, E., Colige, A., & Castronovo, V. (2005) · The FASEB Journal · doi:10.1096/fj.04-2303fje · Cited by 197
“Primary vascular HSMCs were isolated from human umbilical cord vein following a method described previously (42), and primary human skin fibroblasts were established by outgrowth of normal human skin biopsies as detailed elsewhere (43, 44).”
MethodSelf-citationRamalingam, S. S., Parise, R. A., Ramananthan, R. K., Lagattuta, T. F., Musguire, L. A., Stoller, R. G., Potter, D. M., Argiris, A. E., Zwiebel, J. A., Egorin, M. J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0162 · Cited by 193
Histone Deacetylase 7 Silencing Alters Endothelial Cell Migration, a Key Step in Angiogenesis
Mottet, D., Bellahcène, A., Pirotte, S., Waltregny, D., Deroanne, C., Lamour, V., Lidereau, R., & Castronovo, V. (2007) · Circulation Research · doi:10.1161/circresaha.107.149377 · Cited by 192
Self-citationCastro-Rivera, E., Ran, S., Thorpe, P., & Minna, J. D. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0403969101 · Cited by 188
Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets
Bajbouj, K., Al-Ali, A., Ramakrishnan, R. K., Saber-Ayad, M., & Hamid, Q. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111701 · Cited by 176
DNA repair and cisplatin resistance in non-small-cell lung cancer
Rosell, R., Lord, R. V. N., Taron, M., & Reguart, N. (2002) · Lung Cancer · doi:10.1016/s0169-5002(02)00224-6 · Cited by 178
“In addition, HDAC inhibitors can not only relieve gene silencing but also inhibit VEGF expression, acting as antiangiogenic agents [53].”
BackgroundHistone Deacetylase Inhibitors In The Treatment Of Cancer: Overview And Perspectives
Giannini, G., Cabri, W., Fattorusso, C., & Rodriquez, M. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.80 · Cited by 175
Histone Deacetylase: A Potential Therapeutic Target for Fibrotic Disorders
Pang, M., & Zhuang, S. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.168385 · Cited by 173
Histone Deacetylases: A Saga of Perturbed Acetylation Homeostasis in Cancer
Parbin, S., Kar, S., Shilpi, A., Sengupta, D., Deb, M., Rath, S. K., & Patra, S. K. (2014) · Journal of Histochemistry & Cytochemistry · doi:10.1369/0022155413506582 · Cited by 172
“This is clearly evident by the increased levels of HDAC1 in the hypoxic regions of tumors in vivo (Kim et al. 2001; Deroanne et al. 2002).”
BackgroundHDAC inhibitors: Targets for tumor therapy, immune modulation and lung diseases
Shanmugam, G., Rakshit, S., & Sarkar, K. (2022) · Translational Oncology · doi:10.1016/j.tranon.2021.101312 · Cited by 171
Development of vorinostat: Current applications and future perspectives for cancer therapy
Richon, V. M., Garcia-Vargas, J., & Hardwick, J. S. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.01.002 · Cited by 169
“Furthermore, vorinostat is a potent anti-angiogenic agent that can alter VEGF signaling [58].”
BackgroundLi, Z., & Zhu, W.-G. (2014) · International Journal of Biological Sciences · doi:10.7150/ijbs.9067 · Cited by 160
“TSA and SAHA potently inhibit VEGF-induced angiogenesis by repressing VEGF-induced expression of VEGFRs or upregulating VEGF competitor [148].”
BackgroundShankar, S., & Srivastava, R. K. (2008) · Advances in Experimental Medicine and Biology · doi:10.1007/978-1-4020-6554-5_13 · Cited by 160
Ramalingam, S. S., Belani, C. P., Ruel, C., Frankel, P., Gitlitz, B., Koczywas, M., Espinoza-Delgado, I., & Gandara, D. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318191520c · Cited by 159
The role of histone deacetylases in prostate cancer
Abbas, A., & Gupta, S. (2008) · Epigenetics · doi:10.4161/epi.3.6.7273 · Cited by 170
Histone deacetylases: target enzymes for cancer therapy
Mottet, D., & Castronovo, V. (2007) · Clinical & Experimental Metastasis · doi:10.1007/s10585-007-9131-5 · Cited by 158
“We and others demonstrated that HDACi reduced the expression of proangiogenic factors, including VEGF, VEGF receptors 1 and 2 (VEGFR1 and VEGFR2) and neuropilin and enhanced the expression of angiogenic inhibitors such as semaphorin III in endothelial cells [47].”
BackgroundSelf-citationDevelopment of histone deacetylase inhibitors for cancer treatment
Marchion, D., & Münster, P. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.4.583 · Cited by 149
Endothelial Nitric Oxide Synthase: A New Paradigm for Gene Regulation in the Injured Blood Vessel
Tai, S. C., Robb, G. B., & Marsden, P. A. (2004) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000109171.50229.33 · Cited by 153
Histone deacetylase 4 is required for TGFβ1-induced myofibroblastic differentiation
Glenisson, W., Castronovo, V., & Waltregny, D. (2007) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2007.05.016 · Cited by 153
Self-citationHellebrekers, D. M. E. I., Castermans, K., Viré, E., Dings, R. P. M., Hoebers, N. T. H., Mayo, K. H., oude Egbrink, M. G. A., Molema, G., Fuks, F., van Engeland, M., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1609 · Cited by 150
Robb, G. B., Carson, A. R., Tai, S. C., Fish, J. E., Singh, S., Yamada, T., Scherer, S. W., Nakabayashi, K., & Marsden, P. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m400271200 · Cited by 148
Histone deacetylase inhibitors: potential targets responsible for their anti-cancer effect
Dickinson, M., Johnstone, R. W., & Prince, H. M. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9596-y · Cited by 144
“[177, 179–186].”
Identification of Epigenetically Silenced Genes in Tumor Endothelial Cells
Hellebrekers, D. M. E. I., Melotte, V., Viré, E., Langenkamp, E., Molema, G., Fuks, F., Herman, J. G., Van Criekinge, W., Griffioen, A. W., & van Engeland, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3032 · Cited by 137
“Recently, we (12) and others (13, 14) found that DNMT and HDAC inhibitors are also potent angiostatic agents, inhibiting endothelial cell growth and angiogenesis in vitro and in vivo .”
BackgroundDual targeting of epigenetic therapy in cancer
Hellebrekers, D. M. E. I., Griffioen, A. W., & van Engeland, M. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.07.003 · Cited by 162
Lee, E. Q., Reardon, D. A., Schiff, D., Drappatz, J., Muzikansky, A., Grimm, S. A., Norden, A. D., Nayak, L., Beroukhim, R., Rinne, M. L., et al. (2015) · Neuro-Oncology · doi:10.1093/neuonc/nou350 · Cited by 145
The epigenome as a therapeutic target in prostate cancer
Perry, A. S., Watson, R. W. G., Lawler, M., & Hollywood, D. P. (2010) · Nature Reviews Urology · doi:10.1038/nrurol.2010.185 · Cited by 148
Waltregny, D., de Leval, L., Glénisson, W., Tran, S. L., North, B. J., Bellahcène, A., Weidle, U. H., Verdin, E. M., & Castronovo, V. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63320-2 · Cited by 147
“Primary human skin fibroblasts were established by outgrowth of normal human skin biopsies as detailed elsewhere.(34,35) Primary human smooth muscle cells (HSMCs) were harvested from human umbilical cord veins, essentially as previously described,(35,36) after removal of the endothelial cell layer.”
MethodSelf-citationEpigenetic polypharmacology: A new frontier for epi‐drug discovery
Tomaselli, D., Lucidi, A., Rotili, D., & Mai, A. (2020) · Medicinal Research Reviews · doi:10.1002/med.21600 · Cited by 119
Zhang, L., Han, Y., Jiang, Q., Wang, C., Chen, X., Li, X., Xu, F., Jiang, Y., Wang, Q., & Xu, W. (2015) · Medicinal Research Reviews · doi:10.1002/med.21320 · Cited by 125
Godschalk, R., van Schooten, F., & Bartsch, H. (2003) · BMB Reports · doi:10.5483/bmbrep.2003.36.1.001 · Cited by 146
Malignant pleural mesothelioma: The standard of care and challenges for future management
van Meerbeeck, J. P., Scherpereel, A., Surmont, V. F. M., & Baas, P. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.04.004 · Cited by 140
“[89] Deroanne CF, Bonjean K, Servotte S, et al.”
BackgroundGilbert, R. E., Huang, Q., Thai, K., Advani, S. L., Lee, K., Yuen, D. A., Connelly, K. A., & Advani, A. (2011) · Kidney International · doi:10.1038/ki.2011.39 · Cited by 127
Gene Expression Signature Analysis Identifies Vorinostat as a Candidate Therapy for Gastric Cancer
Claerhout, S., Lim, J. Y., Choi, W., Park, Y.-Y., Kim, K., Kim, S.-B., Lee, J.-S., Mills, G. B., & Cho, J. Y. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024662 · Cited by 117
“These inhibitors manifest anticancer effects by inducing the intrinsic and extrinsic apoptosis pathway [27,28], blocking tumor angiogenesis [29], and inhibiting intracellular stress response pathways [30].”
BackgroundHistone Deacetylase in Carcinogenesis and Its Inhibitors as Anti-cancer Agents
Kim, D. H., Kim, M., & Kwon, H.-J. (2003) · BMB Reports · doi:10.5483/bmbrep.2003.36.1.110 · Cited by 146
“We, as well as other groups, have shown that the gene expression regulation through the acetylation of histone is highly involved in the control of angiogenesis (Kim et al., 2001; Kwon et al., 2001; Deroanne et al., 2002).”
BackgroundTakada, Y., Gillenwater, A., Ichikawa, H., & Aggarwal, B. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m507213200 · Cited by 117
Mahalingam, D., Medina, E. C., Esquivel, J., Espitia, C. M., Smith, S. A., Oberheu, K., Swords, R. T., Kelly, K. R., Mita, M. M., Mita, A. C., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1385 · Cited by 123
Aberrant DNA Methylation and Prostate Cancer
Majumdar, S., Buckles, E. L., Estrada, J. J., & Koochekpour, S. (2011) · Current Genomics · doi:10.2174/138920211797904061 · Cited by 127
“These drugs appear in vitro to also increase the efficacy of radiation therapy [196] and they have anti-angiogenesis function [197].”
BackgroundDobosy, J. R., Roberts, J. L., Fu, V. X., & Jarrard, D. F. (2007) · The Journal of Urology · doi:10.1016/j.juro.2006.10.063 · Cited by 131
Hypoxia-induced angiogenesis in human hepatocellular carcinoma
Kim, K.-R., Moon, H.-E., & Kim, K. (2002) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0380-0 · Cited by 122
Gut microbial-derived short-chain fatty acids and bone: a potential role in fracture healing
Wallimann, A., Magrath, W. J., Thompson, K., Moriarty, T. F., Richards, R. G., Akdiş, C. A., O’Mahony, L., & Hernandez, C. J. (2021) · European Cells and Materials · doi:10.22203/ecm.v041a29 · Cited by 115
“Deroanne et al. (2002) showed that the HDAC inhibitor TSA has anti-angiogenic effects by preventing the formation of a capillary-like network of HUVECs, indicating that HDAC inhibition is a crucial mechanism in the prevention of angiogenesis.”
BackgroundŠevčíková, A., Izoldova, N., Števurková, V., Kasperova, B., Chovanec, M., Čierniková, S., & Mego, M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23010488 · Cited by 112
Fath, D. M., Kong, X., Liang, D., Lin, Z., Chou, A., Jiang, Y., Fang, J., Caro, J., & Sang, N. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600456200 · Cited by 108
Angiogenesis and antiangiogenic therapy in non-Hodgkin's lymphoma
Ruan, J., Hajjar, K. A., Rafii, S., & Leonard, J. P. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn666 · Cited by 115
“HDACi can also alter VEGF signaling by inhibiting VEGF receptors and neuropilin-1 expression in endothelial cells [111].”
BackgroundInoue, K., Kobayashi, M., Yano, K., Miura, M., Izumi, A., Mataki, C., Doi, T., Hamakubo, T., Reid, P., Hume, D. A., et al. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000247247.89787.e7 · Cited by 105
Histone Deacetylase Inhibitors as Novel Anticancer Therapeutics
Walkinshaw, D. R., & Yang, X. (2008) · Current Oncology · doi:10.3747/co.v15i5.371 · Cited by 114
Nakao, Y., Yoshida, S., Matsunaga, S., Shindoh, N., Terada, Y., Nagai, K., Yamashita, J. K., Ganesan, A., van Soest, R. W. M., & Fusetani, N. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200602047 · Cited by 109
Posttranslational modifications of histone deacetylases: Implications for cardiovascular diseases
Eom, G. H., & Kook, H. Y. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2014.02.012 · Cited by 105
Effect of Niacin on Inflammation and Angiogenesis in a Murine Model of Ulcerative Colitis
Salem, H. A., & Wadie, W. (2017) · Scientific Reports · doi:10.1038/s41598-017-07280-y · Cited by 95
Targeting histone deacetylases for the treatment of cancer and inflammatory diseases
Huang, L. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20781 · Cited by 98
“…its tyrosine kinase receptor Tie-2, VEGF receptors VEGFR1 and VEGFR2, and neuropilin-1 in endothelial cells, thus directly inhibiting VEGF and bFGF-stimulated endothelial cell proliferation, migration, invasion, and new vessel formation (Deroanne et al., 2002; Qian et al., 2004; Liu et al., 2006).”
BackgroundAcetylation of proteins as novel target for antitumor therapy: Review article
Gennaro, E. D., Bruzzese, F., Caraglia, M., Abruzzese, A., & Budillon, A. (2004) · Amino Acids · doi:10.1007/s00726-004-0087-3 · Cited by 103
“Finally, other mechanisms of antitumor activity of HDAC inhibitors include antiangiogenic properties, through alteration of VEGF signaling (Deroanne et al., 2002) and suppression of tumor invasion, through negative regulation of matrix metalloproteinases expression (Liu et al., 2003).”
BackgroundYang, Q., Tian, Y., Liu, S., Zeine, R. R., Chlenski, A., Salwen, H. R., Henkin, J., & Cohn, S. L. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-2595 · Cited by 94
“Others (42) have indicated that trichostatin A (TSA) and suberoylanilide hydroxamic acid can block angiogenesis and that TSA specifically inhibits hypoxiainduced angiogenesis in the Lewis lung carcinoma model.”
Backgroundp53 at the Crossroads between Different Types of HDAC Inhibitor-Mediated Cancer Cell Death
Mrakovcic, M., Kleinheinz, J., & Fröhlich, L. F. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20102415 · Cited by 85
Enzyme Inhibitors from Marine Invertebrates
Nakao, Y., & Fusetani, N. (2007) · Journal of Natural Products · doi:10.1021/np060600x · Cited by 89
Antiangiogenic Therapy and Mechanisms of Tumor Resistance in Malignant Glioma
Rahman, R., Smith, S. J., Rahman, C. V., & Grundy, R. G. (2010) · Journal of Oncology · doi:10.1155/2010/251231 · Cited by 101
“In human brain tumors it has been shown that miR-296 is elevated in tumor-related endothelial cells of new vessels and that this miRNA may govern growth factor receptor expression [145].”
Background
Metadata
- Authors
- Deroanne, C. F., Bonjean, K., Servotte, S., Devy, L., Colige, A., Clausse, N., Blacher, S., Verdin, E., Foidart, J.-M., Nusgens, B. V., & Castronovo, V.
- Affiliations
- University of Liège (BE)
- University of California, San Francisco (US)
- Corresponding author
- Deroanne, Christophe F
- Venue
- Oncogene
- Published
- 2002-01-17
- Volume
- 21
- Issue
- 3
- Pages
- 427-436
- ISSN
- 0950-9232 (ISSN-L)
- 1476-5594
- OpenAlex
- W2031671750
- Cited by
- 400
- References
- 25
- Citations by year
- 2026: 5 · 2025: 7 · 2024: 6 · 2023: 6 · 2022: 9 · 2021: 24 · 2020: 11 · 2019: 16 · 2018: 10 · 2017: 18 · 2016: 18 · 2015: 18 · 2014: 20 · 2013: 15 · 2012: 27
- FWCI
- 5.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Oncogene (publishedVersion)
- PubMed (publishedVersion)
- Open Repository and Bibliography (University of Liège) (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Health Sciences › Medicine › Oncology › Lymphatic System and Diseases
- Keywords
- histone deacetylase inhibitors, trichostatin A, vorinostat, angiogenesis inhibitors, VEGF signaling, VEGF receptors, VEGFR1, VEGFR2, neuropilin-1, human umbilical vein endothelial cells, capillary formation, angiogenesis, chromatin remodeling
- MeSH terms
- Vorinostat, Animals, Aorta, Carrier Proteins, Cells, Cultured, Chick Embryo, Chorion, Endothelium, Vascular, Histone Deacetylases, Humans, Hydroxamic Acids, Lymphokines, Microscopy, Fluorescence, Microscopy, Phase-Contrast, Nerve Tissue Proteins, RNA, Messenger, RNA, Ribosomal, 28S, Umbilical Veins, Blotting, Western, Signal Transduction, Up-Regulation, Endothelial Growth Factors, Reverse Transcriptase Polymerase Chain Reaction, Angiogenesis Inhibitors, Semaphorin-3A, Vascular Endothelial Growth Factors, Vascular Endothelial Growth Factor A, Rats, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.